Getting your patient started on IMCIVREE
Prescribing IMCIVREE for your patients
1. Download the IMCIVREE Prescription Start Form (preferred method)
Use the Start Form to initiate the prescription and help connect your patient with Rhythm InTune.
2. Complete all fields in the Start Form
Select the appropriate indication and choose the titration and maintenance dose by age and, for ages 2 to <6, by weight.
To enroll in Rhythm InTune, your patient should complete and sign pages 2 and 3.
3. Sign and submit the Start Form
Fax the completed form to 1-877-805-0130 or email patientsupport@rhythmtx.com.
To help avoid unnecessary delays during the insurance approval process:
- Use the IMCIVREE Prescription Start Form
- Complete all fields in the form
- Ensure the appropriate indication and dosage are selected
If e-prescribing, please be sure to:
- Select PANTHERx Rare Pharmacy in the US, or Special Care Pharmacy Services in Puerto Rico
- Consider also submitting the Prescription Start Form, which includes the Rhythm InTune patient consent form and additional information fields often required for insurance approval, as these are not typically included when e-prescribing
Genetic testing
For more information regarding genetic testing or prescribing IMCIVREE for a patient with POMC, PCSK1, or LEPR deficiencies, please contact medinfo@rhythmtx.com or call 1-833-789-6337.
Personalized patient support
Helping patients stay on track along their IMCIVREE journey:
Patient Access
Starting Treatment
Ongoing Treatment
Patients can enroll in Rhythm InTune by completing the consent section of the IMCIVREE Prescription Start Form or can learn more by visiting RhythmInTune.com.
*Patient Education Managers are employees of Rhythm Pharmaceuticals and do not provide medical care or advice. We encourage your patients to always speak to their healthcare providers regarding their medical care.
Learn more about Patient Education Managers
See how they can help your patient along their IMCIVREE journey.
Questions?
For more information about Rhythm InTune, contact us at 1-855-206-0815 (M-F, 8am-6pm ET) or by emailing patientsupport@rhythmtx.com
Preparing your patients for IMCIVREE treatment
Once-daily administration of IMCIVREE can help reduce BMI1
Subcutaneous injection, administered1:
- At the beginning of the day
- With or without food
- In the abdomen, thigh, or arm, rotating injection sites daily
IMCIVREE can be self-administered or given by a caregiver. Refrigerated storage is recommended, with room temperature storage permitted for up to 30 days.1
Reestablishing MC4R pathway function through continuous treatment with IMCIVREE is foundational for effective long-term treatment of obesity due to POMC, PCSK1, or LEPR deficiency.1,2
Follow the titration schedule to reach a maintenance dose to optimize efficacy and tolerability1
| Young Children (2 to <6 years of age) | ||||
|---|---|---|---|---|
| Baseline body weight | Weeks 1-2 (Starting Dose) | Weeks 3-4 | Weeks 5-6 | Week 7 and onward |
| 15 to <20 kg (33-44 lbs) | 0.5 mg once daily (recommended maintenance dose) | |||
| 20 to <30 kg (44-66 lbs) | 0.5 mg once daily | 1.0 mg once daily (recommended maintenance dose) | ||
| 30 to <40 kg (66-88 lbs) | 0.5 mg once daily | 1.0 mg once daily | 1.5 mg once daily (recommended maintenance dose) | |
| ≥40 kg (≥88 lbs) | 0.5 mg once daily | 1.0 mg once daily | 1.5 mg once daily | 2.0 mg once daily (recommended maintenance dose) |
Uptitration: Increase dose by 0.5 mg every 1-2 weeks until recommended maintenance dose by body weight. If the starting dose is:
| ||||
When the child reaches age 6, the maintenance dose increases to 3.0 mg regardless of weight.
| Children (6 to <12 years of age) | ||
|---|---|---|
| Starting Dose (Weeks 1-2) | Uptitration dose (Typically weeks 3-4) | Recommended maintenance dose (Typically weeks 5 and onward) |
| 1.0 mg once daily | 2.0 mg once daily | 3.0 mg once daily |
If the starting
| ||
| Adults and children (≥12 years of age) | |
|---|---|
| Starting Dose (Weeks 1-2) | Recommended maintenance dose (Weeks 3 and onward) |
| 2.0 mg once daily | 3.0 mg once daily |
If the starting
| |
No dose adjustments are needed for patients with mild to moderate renal impairment.1
Effective, long-term weight management starts with setting patient expectations
In clinical trials, it took some time for hunger and weight reductions to be noted, while patients experienced certain AEs soon after starting treatment. This chart highlights some of the most common AEs, but it does not include all reported AEs.1-6
Timing of common effects seen in clinical trials1-6
Weight reduction
Meaningful weight reduction began within 6-8 weeks and continued over time.1-5
Hunger reduction
Hunger reduction began within weeks. Measures of hunger increased quickly upon dose reduction or discontinuation of IMCIVREE.2,3
Nausea and vomiting
Nausea and vomiting were primarily reported within the first 4 weeks of treatment and typically resolved within a few days; nearly all events were mild and none were serious.6
Hyperpigmentation
Hyperpigmentation typically occurred within 2-3 weeks and increased throughout the dose titration period; levels generally plateaued in the initial months of treatment and were sustained over long-term treatment with IMCIVREE.6
Achieving the benefits of treatment with IMCIVREE may take time. Talking to patients about when they can expect weight and hunger benefits and common adverse reactions may help them manage through the short-term treatment initiation to achieve their longer-term goals.
Learn more about patient resources for treatment initiation, including injection training.
AE=adverse event, LEPR=leptin receptor, MC4R=melanocortin-4 receptor, PCSK1=proprotein convertase subtilisin/kexin type 1, POMC=proopiomelanocortin.